Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination of two distinct basal insulins used in the management of diabetes mellitus—insulin detemir and isophane insulin (also known as NPH or neutral protamine Hagedorn insulin). Insulin detemir is a long-acting recombinant human insulin analog that provides prolonged, steady basal insulin coverage with reduced variability and lower risk of hypoglycemia compared to older insulins. Isophane insulin (NPH) is an intermediate-acting human insulin formulation that provides basal glycemic control with an onset of 1–3 hours, peak at 6–8 hours, and duration up to 24 hours. Both agents act by binding to the human insulin receptor, stimulating glucose uptake into muscle and fat tissue while inhibiting hepatic glucose production. The combination would theoretically provide both immediate/intermediate and extended basal glycemic control for patients with type 1 or type 2 diabetes[1][4][7]. There are no widely marketed fixed-dose combinations of these two specific insulins; they are typically used separately or in regimens combining different types for individualized therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on insulin detemir + isophane insulin.